Treatment with pemetrexed based regimes (combination or monotherapy) was found to have favourable patient outcomes in RET, ALK and ROS-1 positive NSCLC compared to KRAS mutated NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.